• Comparable order intake increased 7%
• Income from continuing operations increased to EUR 608 million, compared to EUR 550 million in Q4 2019
• Adjusted EBITA margin increased to 19.0% of sales, compared to 17.9% of sales in Q4 2019
• Income from operations improved to EUR 795 million, compared to EUR 730 million in Q4 2019
• EPS from continuing operations (diluted) amounted to EUR 0.66; Adjusted EPS increased to EUR 0.94, compared to EUR 0.83 in Q4 2019
• Operating cash flow improved to EUR 1,305 million, compared to EUR 1,271 million in Q4 2019
• Free cash flow improved to EUR 1,055 million, compared to EUR 959 million in Q4 2019
Full-year highlights
• Comparable order intake increased 9%
• Income from continuing operations increased to EUR 1,205 million, compared to EUR 1,192 million in 2019
Philips delivers Q4 sales of EUR 6 0 billion, with 7% comp sales growth; income from cont operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19 0%, and operating cash flow increases to EUR 1,305 million | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
DoD Funds Study For Early COVID-19 Symptom Detection Wearable
mhealthintelligence.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mhealthintelligence.com Daily Mail and Mail on Sunday newspapers.
News Category Global Banking & Finance Reviews
Philips, BioIntelliSense and University of Colorado receive U.S. Department of Defense funding for early COVID-19 detection
December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.
December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.